Zenas Biopharma Secures $118 Million To Advance Its Broad Pipeline Of Autoimmune Disease Therapeutics
Amount Raised
$118 Million
Round Type
Funding Round
WalthamBiotechnologyHealth CareTherapeuticsDescription
Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. Existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor, Inc. also participated in the financing, which included the infusion of new capital as well as the conversion of convertible notes issued to certain of the investors in advance of the closing of the Series B financing.
Quick answer
Zenas BioPharma raised $118 Million in a Funding Round round, dated November 7, 2022. Zenas BioPharma is based in Waltham, Massachusetts, United States.
- How much did Zenas BioPharma raise?
- Zenas BioPharma raised $118 Million in a Funding Round round on November 7, 2022.
- What does Zenas BioPharma do?
- Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world.
- Where is Zenas BioPharma based and how big is it?
- Zenas BioPharma is based in Waltham, Massachusetts, United States. Fundz records about 122 employees.
- Who are the decision-makers at Zenas BioPharma?
- Fundz holds 1 contact at Zenas BioPharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Zenas BioPharma that raised within 45 days of this round, from Fundz verified event records.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- QurAlis raised $60M on December 20, 2022.
- Gallant raised $25M on December 15, 2022.
- Alpha-9 Theranostics raised $75M (Series B) on December 14, 2022.
- STORM Therapeutics raised $30M (Series B) on December 14, 2022.
- Peroxitech raised $25M (Series A) on December 13, 2022.
Who to call at Zenas BioPharma, and when
A new round usually means Zenas BioPharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Zenas BioPharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Zenas BioPharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Zenas BioPharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Zenas BioPharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Zenas BioPharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.